BioNTech (BNTX)
(Delayed Data from NSDQ)
$88.09 USD
-0.40 (-0.45%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $88.18 +0.09 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.09 USD
-0.40 (-0.45%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $88.18 +0.09 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Reata (RETA) Soars on Potential Omaveloxolone NDA Filing
by Zacks Equity Research
The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.
Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update
by Zacks Equity Research
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year
by Zacks Equity Research
Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.
BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why
by Zacks Equity Research
BioNTech (BNTX) is riding high on the robust performance of its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year
by Zacks Equity Research
Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis
Find 'Strong Buy' Stocks Near Highs Amid Volatility
by Benjamin Rains
Given this backdrop, investors might want to consider buying stocks that have remained near their highs amid the volatility...
Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon
by Zacks Equity Research
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC
by Zacks Equity Research
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
4 Biotech Stocks That Have Already Doubled This Year So Far
by Kinjel Shah
Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.
Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod
by Zacks Equity Research
The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.
Pfizer (PFE) COVID-19 Vaccine for Adolescents Endorsed by CDC
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) vaccine was 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.
Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Company News for May 11, 2021
by Zacks Equity Research
Companies in the news are: BNTX, WB, ES, J
The Zacks Analyst Blog Highlights: BioNTech, Western Digital and Orient Overseas International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioNTech, Western Digital and Orient Overseas International
3 Fast-Moving Stocks: Global Week Ahead
by John Blank
Most central banks are not yet unwinding money-printing or raising rates, but money supply growth has shrunk. And just how transitory will inflation be?
Stock Market News for May 7, 2021
by Zacks Equity Research
Wall Street closed sharply higher on Thursday following strong labor market Data.
Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.
Panasonic (PCRFY) to Post FY2021 Earnings: What's in Store?
by Zacks Equity Research
Despite accretive collaborations and profitability enhancement endeavors, Panasonic's (PCRFY) fiscal-year 2021 earnings are likely to have been hurt by lower revenues, fueled by COVID-19 adversities.
Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021. Stock up.
Q1 Earnings Season Maintains its Momentum
by Zacks Equity Research
Q1 Earnings Season Maintains its Momentum.
Pfizer, UnderArmour Beat; Trade Deficit at All-Time Low
by Mark Vickery
A sense of caution has begun to permeate the market off near-all-time highs in the indexes, and Pfizer looks to be a recipient of this today.
BioNTech SE Sponsored ADR (BNTX) Stock Jumps 11%: Will It Continue to Soar?
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.